Read this story to learn about Q2- highlights, performance, earnings, dividend updates, market performance, etc.,
Operational revenue surges by 18.5%, showcasing robust Q2 performance.
PAT before exceptional items jumped by an impressive 20% in Q2.
Development & Manufacturing Shine, R&D Boost
Strategic partnerships drive growth in these key service areas. Dedicated research and development services contribute to positive Q2 trends.
Collaborations with Zoetis and Stelis Biopharma mark significant progress. Acquisition of land and FDA authorization further strengthens Syngene's position.